CNS & Neurological Disorders - Drug Targets
Title:Meet Our Editorial Board Member
Volume: 18 Issue: 5
Author(s): Cristoforo Comi
Affiliation:
Export Options
About this article
Cite this article as:
Comi Cristoforo , Meet Our Editorial Board Member, CNS & Neurological Disorders - Drug Targets 2019; 18 (5) . https://dx.doi.org/10.2174/187152731805190620141022
DOI https://dx.doi.org/10.2174/187152731805190620141022 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Functional Selectivity in Cannabinoid Signaling
Current Molecular Pharmacology Revisiting Antipsychotic-induced Akathisia: Current Issues and Prospective Challenges
Current Neuropharmacology Homocysteine Level and Mechanisms of Injury in Parkinson's Disease as Related to MTHFR, MTR, and MTHFD1 Genes Polymorphisms and LDopa Treatment
Current Genomics Safety and Efficacy of Intracoronary Human Umbilical Cord-Derived Mesenchymal Stem Cell Treatment for Very Old Patients with Coronary Chronic Total Occlusion
Current Pharmaceutical Design α7 Nicotinic Acetylcholine Receptor Mediated Neuroprotection in Parkinson’s Disease
Current Drug Targets Caffeine: Cognitive and Physical Performance Enhancer or Psychoactive Drug?
Current Neuropharmacology Neuroprotective Strategies for Neurological Disorders by Natural Products: An update
Current Neuropharmacology Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Schizophrenia: From Dopamine to Glutamate and Back
Current Medicinal Chemistry Serotonin<sub>2c</sub> Receptor Constitutive Activity: In vivo Direct and Indirect Evidence and Functional Significance
Central Nervous System Agents in Medicinal Chemistry A Brief Overview of Tyrosine Hydroxylase and α-Synuclein in the Parkinsonian Brain
CNS & Neurological Disorders - Drug Targets Blocking Striatal Adenosine A2A Receptors: A New Strategy for Basal Ganglia Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Neuropeptide Systems and Schizophrenia
CNS & Neurological Disorders - Drug Targets Colchicine Protects Dopaminergic Neurons in a Rat Model of Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Classical Neurotransmitters and Neuropeptides Involved in Schizophrenia: How to Choose the Appropriate Antipsychotic Drug?
Current Drug Therapy Third Generation Antipsychotic Drugs: Partial Agonism or Receptor Functional Selectivity?
Current Pharmaceutical Design Adult Neurogenesis and Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Tremor and Rigidity in Patients with Parkinson’s Disease: Emphasis on Epidemiology, Pathophysiology and Contributing Factors
CNS & Neurological Disorders - Drug Targets Insights into Structure-Activity Relationships and CNS Therapeutic Applications of NR2B Selective Antagonists
Current Medicinal Chemistry Age-Related Pharmacokinetic and Pharmacodynamic Changes and Related Risk of Adverse Drug Reactions
Current Medicinal Chemistry